ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
Authors
Turner, NBalmaña, J
Fasching, P
Hurvitz, S
Rugo, H
Telli, M
Visco, F
Wardley, Andrew M
Yang, X
Lokker, NA
Lounsbury, DL
Robson, M
Issue Date
2016
Metadata
Show full item recordCitation
ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer 2016, 76 (4 Supplement):OT1-03-17 Cancer ResearchJournal
Cancer ResearchDOI
10.1158/1538-7445.SABCS15-OT1-03-17Type
ArticleLanguage
enISSN
0008-54721538-7445
ae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.SABCS15-OT1-03-17